Latest News

  • REGULATORY

    15 Jan 2026

    FDA opens smoother lanes for CRISPR firms

  • PARTNERSHIPS

    13 Jan 2026

    CRISPR tries to crack the rare-disease problem

  • INNOVATION

    9 Jan 2026

    Why Gene Editing Suddenly Feels Inevitable

  • PARTNERSHIPS

    16 Dec 2025

    A 2021 Gene Editing Deal Still Shapes the Future of Cancer Care

CRISPR Breakthrough Brings Gene Editing Closer to Daily Care

Scientist using pipette for gene-editing research in laboratory

INNOVATION

12 Dec 2025

New trial results suggest gene editing could move from rare use to everyday medicine, pending regulators

CRISPR Pushes Closer to One-Shot Genetic Cures

INNOVATION

31 Oct 2025

CRISPR Pushes Closer to One-Shot Genetic Cures

CRISPR’s CTX460 shows strong AATD results, edging gene therapy closer to one-shot cures

Coding the Cure: Lilly and Verve Team Up on Gene Editing

TECHNOLOGY

29 Oct 2025

Coding the Cure: Lilly and Verve Team Up on Gene Editing

The $1.3 billion Verve deal expands Lilly’s reach into gene editing and next-generation heart therapies

One Infant, One Breakthrough: CRISPR Enters a New Phase

PARTNERSHIPS

28 Oct 2025

One Infant, One Breakthrough: CRISPR Enters a New Phase

Acuitas, CHOP, and Penn pioneer safer, patient-tailored base editing through a landmark CRISPR collaboration

Digital rendering of nanoparticles delivering gene-editing molecules toward target cells.

MARKET TRENDS

7 Aug 2025

Gene Editing’s Next Battle: Cracking the Delivery Code

Biotech firms like Intellia and Editas race to crack CRISPR delivery, a key to market dominance and future gene therapy breakthroughs.

Lilly building with red logo displayed on modern glass architecture.

INVESTMENT

30 Jul 2025

Lilly Bets $1.3B on One-Shot Cure for Heart Disease

Lilly buys Verve Therapeutics to chase a one-time gene edit that could end lifelong cholesterol treatment.

Futuristic DNA helix illustration representing AI-enhanced CRISPR gene editing.

TECHNOLOGY

16 Jul 2025

AI and CRISPR: A Partnership Set to Rewrite Biotech

AI is reshaping how CRISPR therapies reach cells, cutting delays and boosting safety in the race for next-gen gene editing.

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.